Oncodesign Precision Medicine
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a rad… Read more
Oncodesign Precision Medicine (ALOPM) - Total Assets
Latest total assets as of December 2023: €16.63 Million EUR
Based on the latest financial reports, Oncodesign Precision Medicine (ALOPM) holds total assets worth €16.63 Million EUR as of December 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Oncodesign Precision Medicine - Total Assets Trend (2020–2024)
This chart illustrates how Oncodesign Precision Medicine’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Oncodesign Precision Medicine - Asset Composition Analysis
Current Asset Composition (December 2024)
Oncodesign Precision Medicine's total assets of €16.63 Million consist of 80.9% current assets and 19.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 4.1% |
| Accounts Receivable | €624.20K | 5.8% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.08 Million | 10.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Oncodesign Precision Medicine's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oncodesign Precision Medicine's current assets represent 80.9% of total assets in 2024, a decrease from 90.3% in 2020.
- Cash Position: Cash and equivalents constituted 4.1% of total assets in 2024, down from 67.9% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 6.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 10.1% of total assets.
Oncodesign Precision Medicine Competitors by Total Assets
Key competitors of Oncodesign Precision Medicine based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Oncodesign Precision Medicine - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Oncodesign Precision Medicine generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Oncodesign Precision Medicine is currently not profitable relative to its asset base.
Oncodesign Precision Medicine - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.50 | 2.78 | - |
| Quick Ratio | 3.50 | 2.78 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | €10.29 Million | € 8.27 Million | - |
Oncodesign Precision Medicine - Advanced Valuation Insights
This section examines the relationship between Oncodesign Precision Medicine's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.91 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -35.6% |
| Total Assets | €10.71 Million |
| Market Capitalization | $4.73K USD |
Valuation Analysis
Below Book Valuation: The market values Oncodesign Precision Medicine's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Oncodesign Precision Medicine's assets decreased by 35.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Oncodesign Precision Medicine (2020–2024)
The table below shows the annual total assets of Oncodesign Precision Medicine from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €10.71 Million | -35.60% |
| 2023-12-31 | €16.63 Million | -9.46% |
| 2022-12-31 | €18.37 Million | +119.41% |
| 2021-12-31 | €8.37 Million | -32.53% |
| 2020-12-31 | €12.41 Million | -- |